The content on this site is intended for healthcare professionals only

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unrese...

Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland

Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN ( Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland )

ESMO 2022: Breast and ovarian trial analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2022: Breast and ovarian trial analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

ERMES study suggests a strategy of de-escalation with only cetuximab in first li...

Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy

ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC ( Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy )

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA

Neoadjuvant immunotherapy improves outlook in high-risk melanoma ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible loca...

Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York Cit...

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer ( Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York City, USA )

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-li...

Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC ( Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia )

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürma...

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma...

Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy ( Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA )

A new era of early cancer detection with blood test may change cancer screening ...

Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA

A new era of early cancer detection with blood test may change cancer screening paradigms ( Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA )

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable he...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Lenvatinib remains standard of care for first-line therapy in advanced hepatocel...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and...

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Franc...

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

More from ecancer